Streetbeat News

Products Services

CGEM

Cullinan Oncology will present data at the Society for Immunotherapy of Cancer 2023 Annual Meeting, demonstrating progress across its immunotherapy pipeline. The data includes preliminary clinical biomarker data for anti-MICA/B antibody, CLN-619, and highlights the progress of Cullinan's diverse pipeline including CLN-619, CLN-418, CLN-978, and CLN-617.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:08 pm

ABCL

AbCellera has presented new data from its T-cell engager platform at SITC 2023. The data shows that diverse CD3-binding antibodies can optimize T-cell engager function beyond what is possible by modifying a single CD3-binder.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:07 pm

ADAG

Adagene Inc. (NASDAQ:ADAG) presented new data on its masked, anti-CTLA-4 SAFEbody ADG126 at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting. The data demonstrated that ADG126 is effective at targeting CTLA-4 within the tumor microenvironment (TME), resulting in a wider therapeutic index (TI) compared to ipilimumab when combined with anti-PD-1 therapies. The company also reported a clinical case example showing that ADG126 plus pembrolizumab resulted in a confirmed partial response in a patient with advanced/metastatic MSS CRC.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:07 pm

AFMD

Affimed presented preclinical data at the 38th Annual Meeting of the Society for Immunotherapy of Cancer, showing that the addition of its innate cell engager (ICE) improves the cytotoxicity of natural killer (NK) and CAR-NK cells. The use of ICE with NK cells eliminates the need for complex and costly manufacturing compared to CAR-NK cells, and offers flexibility to be used with NK cells from different sources.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:06 pm

ALLO

Allogene Therapeutics, Inc. (NASDAQ:ALLO) presented data on its next generation Cloak and Dagger technologies at the Society for Immunotherapy of Cancer Annual Meeting. These technologies are designed to enhance the performance of AlloCAR T cell candidates and control immune rejection. The Cloak technology prevents AlloCAR T cells from being recognized by host T cells, while the Dagger technology arms AlloCAR T cells with a CD70 CAR designed to recognize and deplete CD70-positive host immune cells. The Dagger technology is a feature of ALLO-316, currently being investigated in a Phase 1 study for solid tumors.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:06 pm

BCRX

BioCryst Pharmaceuticals (BCRX) has announced a diversified pipeline of first-in-class/best-in-class therapies, with five programs expected to enter clinical development in the next 24 months. The programs include BCX17725 for Netherton syndrome, a bifunctional fusion protein, an oral C5 program for generalized myasthenia gravis, and a combination of avoralstat with SCS Microinjector® from Clearside for DME treatment.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:05 pm

ALLO

Allogene Therapeutics, Inc. (NASDAQ:ALLO) presented preclinical data on a novel AlloCAR T product candidate targeting Claudin18.2 (CLDN18.2)-positive gastric and pancreatic tumors at the Society for Immunotherapy of Cancer (SITC) Annual Meeting. The data suggests the potential to provide clinical benefit to patients with a single, off-the-shelf infusion. The preclinical evaluation identified candidates with potent activity in both short-term and repeat stimulation in vitro cytotoxicity assays. ALLO-182, currently in the IND-enabling phase of development, is based on these data.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:05 pm

CADL

Candel Therapeutics announced positive interim data from a randomized Phase 2 clinical trial of CAN-2409 in non-metastatic pancreatic cancer. The data showed notable improvements in patients with borderline resectable pancreatic ductal adenorcarcinoma (PDAC) after treatment with CAN-2409. The overall survival rate was 71.4% at 36 months in CAN-2409 treated patients versus 16.7% in the control arm. Safety analysis demonstrated that multiple injections of CAN-2409 were generally well tolerated.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:04 pm

CUE

Cue Biopharma (NASDAQ:CUE) has presented positive data from its Phase 1 trials of CUE-101 and CUE-102 at the Society for Immunotherapy of Cancer's 38th Anniversary Annual Meeting. The trials showed promising results in treating head and neck cancer and Wilms' Tumor 1 positive cancers. The company reported an overall response rate of 47% and disease control rate of 65% in patients treated with CUE-101 and KEYTRUDA. The median overall survival of patients treated with CUE-101 monotherapy was 20.8 months, significantly higher than the historical average of eight months. CUE-102 also showed promising results with a disease control rate of 75%-80% at the 4mg/kg and 2mg/kg doses.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:04 pm

RAPT

RAPT Therapeutics has announced data from its Phase 2 trial of FLX475 in combination with a checkpoint inhibitor in patients with advanced non-small cell lung cancer (NSCLC). The trial showed a confirmed objective response rate (ORR) of 40% in PD-L1 positive patients with no prior checkpoint inhibitor therapy and a median progression-free survival (PFS) of 6.3 months. The company plans to advance the development of FLX475 based on these results.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:03 pm